In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: influence of thalidomide and high-dose chemotherapy treatment.

Schütt, P; Buttkereit, U; Brandhorst, D; Lindemann, M; Schmiedl, S; Grosse-Wilde, H; Seeber, S; Nowrousian, MR; Opalka, B; Moritz, T

Journal article

In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: influence of thalidomide and high-dose chemotherapy treatment.

Abstract:: While vaccination with antigen-pulsed dendritic cells (DCs) represents a promising therapeutic strategy in multiple myeloma (MM), clinical benefit, so far, has been limited to individual patients. To identify potential problems with this approach, we have analyzed the influence of treatment parameters, in particular high-dose chemotherapy (HD-CTX) and thalidomide, on in vitro DC generation and peripheral blood lymphocyte subsets in MM patients. From a total of 25 MM patients, including 14 patients on thalidomide treatment and 11 after HD-CTX, in vitro DC generation from peripheral blood monocytes under serum-free condition was investigated. In addition, peripheral blood lymphocyte subsets were assessed in 17 patients including 10 patients on thalidomide treatment and 9 patients after HD-CTX. Efficient in vitro generation of DCs (median 7.1x10(6)/100 ml peripheral blood; range 0.1-42.5x10(6)/100 ml peripheral blood) expressing DC-typical surface markers was observed in 23 MM patients (92%), although reduced expression of CD1a, CD40, CD83, and HLA-DR was observed in patients treated with thalidomide. With respect to lymphocyte subsets, MM patients showed significantly (p<0.05) reduced B and CD4+ lymphocytes in the peripheral blood. This effect was most prominent within 6 months of HD-CTX and in patients receiving thalidomide (usually in combination with CTX). CD8+ lymphocytes were significantly increased in MM patients. Thus, despite the well-known deficiencies in their immune system, adequate numbers of DCs can be generated in most myeloma patients. In patients treated with thalidomide, however, it remains to be seen whether the reduced expression of co-stimulatory molecules has functional relevance.

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Schütt, P., Buttkereit, U., Brandhorst, D., Lindemann, M., Schmiedl, S., Grosse-Wilde, H., Seeber, S., Nowrousian, M. R., Opalka, B., & Moritz, T. (2005). In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: influence of thalidomide and high-dose chemotherapy treatment. Cancer Immunology, Immunotherapy : CII, 54(5), 506–512.

MLA Style

Schütt, P., et al. “In Vitro Dendritic Cell Generation and Lymphocyte Subsets in Myeloma Patients: Influence of Thalidomide and High-Dose Chemotherapy Treatment.” Cancer Immunology, Immunotherapy : CII, vol. 54, no. 5, 2005, pp. 506–12.

Chicago Style

Schütt, P, U Buttkereit, D Brandhorst, M Lindemann, S Schmiedl, H Grosse-Wilde, S Seeber, MR Nowrousian, B Opalka, and T Moritz. 2005. “In Vitro Dendritic Cell Generation and Lymphocyte Subsets in Myeloma Patients: Influence of Thalidomide and High-Dose Chemotherapy Treatment.” Cancer Immunology, Immunotherapy : CII 54 (5): 506–12.
Share
Print